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Phenotypic factors associated with
amisulpride-induced weight gain in
ﬁrst-episode psychosis patients
(from the OPTiMiSE cohort)
Pandit R, Cianci D, ter Hark SE, Winter-van Rossum I, Ebdrup BH,
Broberg BV, Garcia-Portilla MP, Bobes J, Vinkers CH, Kahn RS,
Guloksuz S, Huitema ADR, Luykx JJ. Phenotypic factors associated
with amisulpride-induced weight gain in ﬁrst-episode psychosis patients
(from the OPTiMiSE cohort).
Objective: Antipsychotic-induced weight gain (AiWG) is a debilitating
adverse eﬀect of most antipsychotics. First-episode psychosis patients
are particularly vulnerable to the detrimental consequences of AiWG.
Amisulpride has good eﬃcacy and tolerability. We here aimed to
identify the phenotypic factors associated with amisulpride-induced
weight gain in ﬁrst-episode psychosis patients.
Method: Data were collected from the Optimization of Treatment and
Management of Schizophrenia in Europe trial. Multivariable regression
models with various phenotypic variables (N = 305) were performed
with absolute AiWG and clinically relevant AiWG (≥7% AiWG) as
outcomes.
Results: Four weeks of amisulpride treatment increased body weight
from 69.7 to 72.4 kg (P < 0.001). In the regression model of absolute
AiWG, unemployment (b = 0.94, P = 0.016), younger age (b = 0.07,
P = 0.031) and absence of current comorbid major depression disorder
(b = 1.61, P = 0.034) were positively associated with absolute AiWG.
In the regression model of clinically relevant AiWG, unemployment
(OR = 2.83, P = 0.001), schizophreniform disorder (OR = 2.00,
P = 0.025) and low baseline weight (OR = 0.97, P = 0.032) increased
the likelihood of clinically relevant AiWG.
Conclusions: Clinicians prescribing amisulpride should consider the
relatively high susceptibility to AiWG in unemployed ﬁrst-episode
patients with psychosis, in particular young subjects with a diagnosis of
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Summations
• Variables associated with amisulpride-induced weight gain are as follows: unemployment, absence of
current comorbid depression, a diagnosis of schizophreniform disorder, young age and low baseline
weight.
• Several phenotypic variables previously associated with antipsychotic-induced weight gain were not
found to be associated with amisulpride-induced weight gain.
Limitations
• Although our sample size was fairly large and the association between amisulpride-induced weight gain
with unemployment was validated across models, a replication cohort was unavailable as the clinical
trial where we drew our data from is unique in its kind.
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schizophreniform disorder. We advise to carefully monitor these
patients and, when needed, implement weight-reducing strategies.
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Introduction
Antipsychotic-induced weight gain (AiWG) is one of
the most common side-eﬀects of antipsychotics and
is a well-known risk factor for type 2 diabetes melli-
tus and metabolic syndrome (1). The prevalence of
metabolic syndrome in patients treated with antipsy-
chotics is almost twice that of unmedicated
schizophrenia patients (2). AiWG also carries psy-
chosocial consequences such as lower self-esteem
and social isolation which may subsequently trigger
treatment non-adherence (3). These consequences of
AiWG not only negatively inﬂuence the eﬀectiveness
of antipsychotic therapy but they also aﬀect quality
of life and mortality in patients using antipsychotics
(4). In fact, cardiovascular diseases as a result of
metabolic syndrome are one of the leading causes of
mortality in schizophrenia patients (4). Strikingly,
ﬁrst-episode psychosis patients seem particularly vul-
nerable to AiWG (5). To date, several demographic
and clinical factors have been associated with AiWG,
most importantly young age, female sex, non-white
ethnicity, higher antipsychotic dose and lower BMI
(6–8).
Amisulpride is a second-generation dopamine
receptor antagonist and has been shown to be one
of the most eﬀective ﬁrst-line treatment options in
ﬁrst-episode schizophrenia patients (9). Both
short- and long-term treatments with amisulpride
have been associated with clinically relevant AiWG
(≥7% body weight change from baseline) in about
one-ﬁfth of the patients (9–11). Although the
weight gain ﬁgures following amisulpride use are
lower compared to other second-generation
antipsychotics (12), for example weight gain due to
clozapine or olanzapine can be as high as 50%,
labelling amisulpride as a weight-neutral drug
seems unjustiﬁed (12). With few exceptions (13),
the majority of studies investigating amisulpride-
induced weight gain have focused on long-term
treatment with amisulpride (12, 14, 15). Moreover,
the inﬂuence of sociodemographic factors (age,
sex, ethnicity) and dosing on amisulpride-induced
weight gain is poorly understood (8), possibly due
to its labelling as a weight-neutral drug. Further-
more, the eﬀects of unemployment, a risk factor
for weight gain in the general population (16), have
to our knowledge not been studied in relation to
AiWG. Economic uncertainty (16, 17) or passive
lifestyle (18, 19) that are both associated with
unemployment – can trigger weight gain through
unhealthy food choices and decreased physical
activity. Similarly, eﬀects of additional factors
such as baseline psychopathology and presence of
comorbid major depressive disorder (MDD) that
may also negatively aﬀect food choices and thus
stimulate weight gain have to the best of our
knowledge not been investigated in this context
either (17). Awareness about the sociodemographic
and clinical factors associated with amisulpride-
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induced weight gain will help clinicians identify
patients at risk of AiWG, thus allowing them to
monitor more closely and possibly treat AiWG.
Aims of the study
To comprehensively dissect the phenotypic factors
associated with amisulpride-induced weight gain,
we leveraged the size and homogeneity of the
OPTiMiSE (Optimization of Treatment and Man-
agement of Schizophrenia in Europe) trial (9). We
identiﬁed several variables that may be used in
clinical practice to help clinicians monitor amisul-
pride-induced weight gain more closely.
Methods
Clinical trial registration
The data analysed in the current studywere obtained
from theOPTiMiSE trial that is registered with Clin-
icalTrials.gov, number NCT01248195 (9, 20). The
authors assert that all procedures contributing to
this work comply with the ethical standards of the
relevant national and institutional committees on
human experimentation and with the Helsinki Dec-
laration of 1975, as revised in 2008. All procedures
involving human subjects/patients were approved by
the Medical Ethical Committee at the Sponsor site,
University Medical Center Utrecht, the Nether-
lands, under registration number 11-006/G-E and
NL34602.041.11. Regulatory approval was obtained
in each individual country.
Design, intervention and data collection
Details on study design and procedures, inclusion
and exclusion criteria have been described previ-
ously (9). Brieﬂy, ﬁrst-episode patients diagnosed
with schizophrenia between 18 and 40 years of age
were included in the trial. Patients with prior use
of antipsychotics more than 2 weeks in the year
before enrolment or 6 weeks lifetime were
excluded. Written informed consent was obtained
from all patients (20). Data were drawn from the
ﬁrst of three treatment phases of the OPTiMiSE
trial: this was a 4-week open-label, single-arm trial
of treatment with amisulpride at the optimal dose
(200–800 mg/day) was analysed in the current arti-
cle. Nine patients receiving a dose higher than
800 mg/day were also included in the analyses.
Study sites had been instructed to measure weight
as consistently as possible across visits and subjects
(e.g. using the same scale and having patients
either wear or not wear clothes during measure-
ments).
Statistical analysis
Weight gain was deﬁned as the diﬀerence in
weight between the screening visit (a maximum
of 1 week before initiation of phase I) and the
end of the aforementioned phase I trial of
amisulpride. Quantitative data were summarized
as means and standard deviations (SD), while
categorical variables were reported as counts
with percentages. Change in body weight was
tested using student’s t-test (alpha = 0.05). Our
initial study population consisted of 320 patients
(Table S1).
We ran a multivariable linear regression model
with absolute body weight gain as outcome and a
multivariable logistic regression model with clini-
cally signiﬁcant body weight gain as outcome and
the following variables that were assessed at base-
line.
Variables previously associated with AiWG. The
variables, age, sex, race and dose, and prior
antipsychotic exposure have been previously
associated with AiWG (7, 8) and were included
as predictor variables in both statistical models.
Based on the available literature (7), we further
included absolute antipsychotic na€ıveness (de-
ﬁned as no prior exposure to antipsychotics life-
time as reported by the participant) as a
dichotomous variable into our statistical model
given possible eﬀects of any prior exposure (i.e.
short duration of exposure: <2 weeks in the year
before enrolment or <6 weeks lifetime). Likewise,
eﬀects of symptom severity as determined by
PANSS (Positive and Negative Syndrome Scale)
scores and treatment setting (in-patient vs. out-
patient) were added to both statistical models.
Diagnoses of schizophrenia spectrum disorder
and current comorbid MDD were established
according to the Mini International Neuropsy-
chiatric Interview 5 plus (21).
Variables previously associated with weight gain in the
general population. The variables employment sta-
tus and comorbid MDD have been associated with
weight gain in the general population (16, 17) and
were therefore included in the current analyses.
Additional variables. We included diagnostic sub-
type of schizophrenia spectrum disorder as a proxy
for disease severity/duration and treatment setting
(in-patient vs. out-patient) as a proxy for compli-
ance in both statistical models. For the diagnostic
subtype variable, schizophrenia (N = 166) and
schizoaﬀective disorder (N = 18) patients were
pooled into one group given their similarities in
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duration of illness relative to schizophreniform dis-
order patients (N = 136).
Thus, multivariable linear regression analysis
was performed to investigate the association
between sociodemographic factors (age, sex, race
and employment status), baseline diagnosis
(schizophreniform vs. schizophrenia), PANSS
total scores at baseline, presence of current comor-
bid MDD, and treatment-related factors (treat-
ment setting, average dose and prior antipsychotic
exposure) with absolute body weight gain. Logistic
regression was performed with the same variables
to study the association between these factors and
clinically relevant body weight gain (deﬁned as
body weight change of 7% from baseline values
(12)). Both statistical models were corrected for
body weight at baseline. Due to missing data for
the variable of current comorbid MDD, 15 sub-
jects were excluded, resulting in 305 subjects avail-
able for the regression analyses (for the other
variables, all data were complete). Results of the
linear regression are reported as b coeﬃcients with
95% conﬁdence intervals (CI), and results of the
logistic regression are reported as odds ratios (OR)
with 95% CI. The level of statistical signiﬁcance
was set to P < 0.05, two-sided. Statistical analyses
were performed in SPSS version 23 (IBM Corp,
Armonk, NY).
Results
A total of 446 patients were enrolled in the trial,
and 371 patients completed phase I of the study.
We included data on body weight at inception and
end of phase I, which comprised 320 patients
(Table 1). Four weeks of amisulpride therapy led
to a statistically signiﬁcant increase in absolute
body weight from 69.7 (14.3) at baseline to 72.4
(14.3) at end of phase I (t-test, P < 0.001), with
minimal diﬀerences in the degree of AiWG across
sites (Fig. S1). Eleven per cent of normal weight
(BMI 20-25) patients at trial inception became
overweight or obese at the end of phase I
(Table S2).
The assumptions for linearity, normality,
homoscedasticity and absence of multicollinearity
were met in the linear regression model. Unem-
ployment (b = 0.94, P = 0.016) positively con-
tributed to AiWG, while age (b = 0.07,
P = 0.031) and current comorbid major depression
disorder (b = 1.6, P = 0.034) had a negative
eﬀect on AiWG (Table 2). Based on the results of
the linear regression model, unemployed subjects
showed an average AiWG of 3.14 kg (0.82), which
was 1.4 times higher than in employed subjects:
2.21 kg (0.83) (Fig. 1). AiWG in patients without
current comorbid MDD was 2.84 kg (0.85), which
was almost 2.5 times higher than in those with
MDD: 1.16 kg (0.75) (Fig. 1).
Clinically relevant AiWG was observed in 70
(21.9%) patients. Logistic regression was per-
formed to study the eﬀect of the factors listed in
Table 1 on clinically relevant AiWG. Unemploy-
ment and diagnosis of schizophreniform disorder
showed a positive relationship with clinically rele-
vant AiWG: unemployed patients had 2.8 times
greater odds of clinically relevant AiWG than
employed patients (OR 2.83, P = 0.001). Addition-
ally, the odds of clinically relevant AiWG were 2
times greater in patients with a diagnosis of
schizophreniform disorder than in patients with a
diagnosis of schizophrenia or schizoaﬀective disor-
der (OR 2.0, P = 0.025). Those with relatively high
body weight at baseline had smaller odds of suﬀer-
ing from clinically relevant AiWG (OR 0.97,
P = 0.032).
Table 1. Characteristics of patients at baseline categorized on the basis of clinically
relevant body weight gain. Clinically relevant body weight gain is defined as body
weight change of 7% from baseline values. Data represented as mean (SD) or count
Factors
Participants with
<7% body weight
gain (N = 250)
Participants with
≥7% body weight
gain (N = 70)
All
participants
(N = 320)
Sociodemographic variables
Age (years) 26.5 (6.2) 25.1 (5.3) 26.2 (6.08)
Sex
Women 71 (28.4%) 21 (30%) 92 (28.7%)
Men 179 (71.6%) 49 (70%) 228 (71.3%)
Race
White 222 (88.8%) 63 (90%) 285 (89.1 %)
Other 28 (11.2%) 7 (10%) 35 (10.9%)
Employment status
Unemployed 130 (52%) 50 (71.4%) 180 (56.3%)
Employed or
student
120 (48%) 20 (28.6%) 140 (43.7%)
Clinical variables
Primary diagnosis
Schizophreniform
disorder
96 (38.4%) 40 (58.1%) 136 (42.5%)
Schizophrenia 154 (61.6%) 30 (42.9%) 184 (57.5%)
Comorbid MDD†
Yes 18 (7.6%) 2 (2.9%) 20 (6.6%)
No 218 (92.4%) 67 (97.1%) 285 (93.4%)
PANSS total scores‡ 78.9 (19.0) 72.9 (17.7) 77.7 (18.9)
Treatment-related variables
Antipsychotic na€ıveness§
Yes 107 (42.8%) 23 (32.9%) 130 (40.6%)
No 143 (57.2%) 47 (67.1%) 190 (59.4%)
Type of care at baseline
In-patient 155 (62%) 43 (61.4%) 198 (61.9%)
Out-patient 95 (38%) 27 (38.6%) 122 (38.1%)
Average dose (mg/day) 480.6 (202) 462.8 (212) 476.7 (204.3)
†Major depressive disorder (MDD) diagnoses were available for 305 patients of
whom 236 patients showed non-significant and 69 patients significant body weight
gain.
‡PANSS: Positive and Negative Syndrome Scale, total scores (ranging from 30 to
210), with high scores indicating more severe psychopathology.
§Defined as no prior exposure to antipsychotics lifetime.
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Discussion
We here characterized clinical and sociodemo-
graphic factors associated with amisulpride-in-
duced weight gain in a homogeneous, relatively
large cohort (n = 305) of ﬁrst-episode psychosis
patients following a month of treatment of amisul-
pride. We identify unemployment, young age,
absence of current comorbid MDD, diagnosis of
schizophreniform disorder, and lower body
weight at baseline as factors positively associated
with amisulpride-induced weight gain.
Unemployment rates amongst patients with psy-
chosis are often higher than 50% (22). This obser-
vation is also reﬂected in our current cohort where
56.3% of the patients were unemployed. We
observed higher AiWG in unemployed patients
using amisulpride than in employed participants of
the trial. To our knowledge, this is the ﬁrst study
to report this association. In the general popula-
tion, unemployment is a risk factor for body
weight gain as it negatively aﬀects food choices
(17, 23). Similarly, low income due to unemploy-
ment could limit access to a healthy lifestyle (dieti-
cians and sports facilities) (17, 23), in turn
increasing the risk of weight gain. These indirect
eﬀects of unemployment have also been reported
in schizophrenia patients (22) and may explain the
accelerated weight gain detected here in unem-
ployed participants. Another explanation for the
high degree of AiWG observed in unemployed
subjects could be a diminished sense of belonging,
which may result in a passive lifestyle and thus
increase chances of weight gain (18, 19). The rela-
tionship between MDD and weight gain may be
explained by two phenomena. First, sedentary life-
style due to fatigue and anhedonia may promote
weight gain (17). Second, loss of appetite may trig-
ger weight loss (24). The latter likely explains the
lower body weight gain in subjects with MDD
observed in our cohort. This is also in agreement
with previous observations of weight loss rather
than weight gain in depressed adolescents and
adults (25). The negative association between age
and AiWG observed in our cohort has previously
Fig. 1. Amisulpride-induced weight gain by employment status
and current comorbid diagnosis of major depressive disorder
(MDD) based on the results of the linear regression model.
Data are shown as mean and standard deviations (whiskers).
Table 2. Results of multivariable linear regression (light grey) and logistic regression models (dark grey). b coefficients for linear regression and odds ratios (OR) for logistic
regression are provided with their corresponding 95% confidence intervals (CI) and p-values. In bold are statistically significant (p=<0.05) findings
Predictor variables
Linear regression Logistic regression
Outcome variable: Delta body weight
Outcome variable: Clinically relevant
weight gain
b 95% CI P-value OR 95% CI P-value
Sociodemographic variables
Age (years) 0.07 0.13, 0.01 0.031 0.96 0.91, 1.01 0.106
Sex (male vs. female) 0.01 0.89, 0.92 0.982 0.94 0.46, 1.89 0.852
Race (white vs. others) 0.16 1.04, 1.35 0.798 1.34 0.52, 3.44 0.545
Unemployed (yes or no) 0.94 0.18, 1.71 0.016 2.83 1.50, 5.36 0.001
Baseline psychopathology associated variables
Primary diagnosis (schizophreniform disorder vs. schizophrenia)† 0.59 0.20, 1.37 0.141 2.00 1.09, 3.68 0.025
Current comorbid MDD (yes vs. no)† 1.61 3.10, 0.12 0.034 0.39 0.08, 1.79 0.224
PANSS total Scores‡ 0.01 0.03, 0.01 0.380 0.99 0.97, 1.00 0.085
Treatment-related variables
Antipsychotic na€ıve (yes vs. no) 0.50 1.32, 0.33 0.235 0.72 0.37, 1.42 0.345
Type of care at baseline (in-patient vs. out-patient) 0.27 1.14, 0.60 0.537 1.34 0.67, 2.67 0.407
Average dose (mg/day) 0.00 0.00, 0.00 0.824 0.99 0.99, 1.00 0.087
Baseline body weight (kg) 0.02 0.05, 0.01 0.182 0.97 0.95, 0.99 0.032
†According to the Mini International Neuropsychiatric Interview 5 plus.
‡PANSS: Positive and Negative Syndrome Scale, total scores (ranging from 30 to 210), with high scores indicating more severe psychopathology.
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been reported for other antipsychotics (6, 26), but
not for amisulpride (8).
In the current cohort, patients with clinically rel-
evant body weight gain had a lower baseline body
weight. This ﬁnding has been reported by others
and has been observed both in antipsychotic-na€ıve
and pre-exposed patients (7, 8). Although the exact
mechanism remains unknown, higher appetite
levels and binge-eating may explain part of this
phenomenon (26).
While a positive association between symptom
improvement and AiWG has been reported previ-
ously (27), we observed no correlation between
change in PANSS scores and body weight change
(Fig. S2). However, independent of other variables
such as age and employment status, a higher per-
centage of the patients with ≥7% AiWG had been
diagnosed with schizophreniform disorder, which
is characterized by a shorter duration of symptoms
and usually better prognosis than schizophrenia
(28). We speculate that shorter duration of illness
is associated with better treatment adherence and
thus relatively high weight increases due to true
amisulpride use. In support of this hypothesis,
higher remission rates were indeed found in
schizophreniform patients in the OPTiMiSE study
(9).
Phenotypes previously associated with AiWG in
response to other antipsychotics (e.g. antipsy-
chotic-na€ıve status, sex and race) were not associ-
ated with amisulpride-induced weight gain in the
current study. We speculate that diﬀerences in the
pharmacological proﬁles (1) between second-gen-
eration antipsychotics may underlie this observa-
tion.
Strengths and limitations
Our understanding of AiWG especially in ﬁrst-
episode psychosis patients is limited. Our ﬁrst
model (the linear regression model) is most
informative because it uses weight as a continu-
ous variable, while the second model (the logistic
regression model) is directly applicable to clinical
settings as this concerns clinically relevant
AiWG. It additionally facilitates literature com-
parison (12) on weight gain with other antipsy-
chotics. Despite clear advantages of our study
design (e.g. the homogeneity and size of the
cohort and the two statistical models providing
consistent results), our results should be inter-
preted in light of some limitations. First,
although comparing the weight-inducing eﬀects
of amisulpride with an untreated control arm
would have been ideal, matching these two
groups on all sociodemographic factors would
be impossible due to the unethical nature of
withholding treatment. We cannot exclude other
factors in addition to the use of amisulpride
explaining a part of the increase in body weight.
This constitutes a general drawback in single-
arm studies (29). Second, there is the issue of
adherence introducing uncertainty in the reliabil-
ity of the results, a recurring theme in many
clinical trials. To address this uncertainty, we
included type of care (in-patient vs. out-patient)
as in-patients are more likely to be treatment
compliant but this proxy may not fully capture
all variation in adherence. Finally, we have tried
to incorporate as many clinical and sociodemo-
graphic variables as possible in our statistical
models – variables hitherto not associated with
AiWG and those previously associated with both
AiWG and weight gain in the general popula-
tion. However, possibly other relevant variables
not measured in the OPTiMiSE trial may impact
amisulpride-induced weight gain too. For exam-
ple, as income was not comprehensively assessed
in OPTiMiSE, we cannot disentangle how this
factor contributes to AiWG. In addition, genetic
factors may also contribute to amisulpride-in-
duced weight gain, which is the subject of
another study (manuscript in review). On a simi-
lar note, not all subgroups were equally repre-
sented, impacting statistical power for some of
the variables we tested, such as race.
Concluding remarks and future research
In sum, the current study is the ﬁrst comprehen-
sive study investigating clinical and sociodemo-
graphic factors associated with amisulpride use.
The consistent association between unemploy-
ment and amisulpride-induced weight gain across
statistical models should prompt caution in clini-
cians prescribing amisulpride for this vulnerable
patient population. Monitoring of this group is
advisable to reduce chances of non-adherence.
Furthermore, implementation of timely weight
management strategies may be considered in
unemployed subjects to diminish the morbidity
and mortality associated with metabolic syn-
drome. Similarly to the unemployed group,
patients with schizophreniform disorder show a
higher propensity to amisulpride-induced weight
gain relative to subjects with schizophrenia. They
should therefore also be closely monitored.
Finally, as predictors of AiWG may diﬀer across
antipsychotics, diﬀerences in susceptibility to
AiWG between individuals and between antipsy-
chotics should be further investigated in future
genome-wide studies.
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Supporting Information
Additional Supporting Information may be found in the online
version of this article:
Table S1. The number and percentage of participants per-site
included in the current study.
Table S2. Shift in BMI categories from inception to the end of
trial, expressed as numbers and percentages of initial BMI cat-
egories: underweight (BMI<20); normal weight (BMI 20-25);
and overweight (BMI>25).
Fig. S1. Body weight gain (kg) across sites following 4-week
treatment of Amisulpride.
Fig. S2. A bivariate correlational analysis between change in
total PANSS scores and body weight change R2 = 0.002 and
P = 0.415.
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